Abstract:Abstract The understanding of the biological role of BRCA1 in maintaining genomic integrity through homologous recombination (HR) repair has driven the development of targeted treatments with PARP inhibitors (PARPi) in BRCA1-linked tumors with promising results. Recently, cyclin-dependent kinase 9 (CDK9) inhibitors have emerged as therapeutic options to treat cancer. We have previously implicated CDK9 in genome integrity maintenance through HR repair by modulating BRCA1 recruitment to double-stranded break sites. CDK9 is a component of the positive transcription elongation (PTEF-b) complex and more recently was proposed by the hereditary breast case-control (BEACCON) study as a putative breast cancer (BC) predisposition gene in non-BRCA families. Differently from BRCA1-linked BCs, loss-of-function mutations in CDK9 were significantly correlated with ER-positive and Lobular BCs. CDK9 expression is also elevated in metastatic and recurrent ovarian cancer (OC) tissue and correlates with poor prognosis in OC patients. Here we characterize the BRCA1/BARD1/CDK9 complex using protein-protein interaction assays. Our data indicate that the CDK9/BARD1 interaction occurs indirectly through BRCA1. We also generated a separation-of-function mutation in CDK9 (mutCDK9) that disrupts its interaction with BRCA1 but retains its kinase activity and preserves its role in transcription. We rescued the mutCDK9/BRCA1 interaction using a complementary mutation in BRCA1 (cmutBRCA1), that retains BRCA1 role in cell viability. Further, we employed CRISPR-based genome editing to generate genetically defined haploid HAP1 cell lines that express mutCDK9 in various TP53BP1 and BRCA1 backgrounds. The mutCDK9 cells preserve global RNA transcription and the phosphorylation status of the RNA polymerase II. We observed that mutCDK9 cells are more sensitive to the PARPi, rucaparib when compared to wild-type cells in proficient and deficient TP53BP1 backgrounds. However, mutCDK9 expression did not affect the sensitivity of HAP1 cells expressing cmutBRCA1. Collectively, our data suggest that CDK9 acts in genome integrity maintenance by HR through its interaction with BRCA1 independently of its canonical role in transcription. Citation Format: Thales C. Nepomuceno, Marcelo A. Carvalho, Alvaro N. Monteiro. The BRCA1-associated role of CDK9 in response to DNA damage is independent of its canonical role in transcription [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5608.

CDK7/CDK9 mediates transcriptional activation to prime paraptosis in cancer cells

Abstract 4326: CDK7/CDK9 mediates transcriptional regulation to prime cancer cell paraptosis

Exploring paraptosis as a therapeutic approach in cancer treatment

Targeting paraptosis in cancer: opportunities and challenges

Paraptosis: a non-classical paradigm of cell death for cancer therapy

Parthanatos And Its Associated Components: Promising Therapeutic Targets For Cancer

The Mediator Captures CDK7, an Attractive Transcriptional Target in Cancer.

Targeting CDK9 for Anti-Cancer Therapeutics

Abstract 5608: The BRCA1-associated role of CDK9 in response to DNA damage is independent of its canonical role in transcription

Targeting cyclin-dependent kinase 9 in cancer therapy

CDK7-dependent Transcriptional Addiction in Triple-Negative Breast Cancer.

CDK9 inhibition activates innate immune response through viral mimicry

THZ1 Reveals CDK7-dependent Transcriptional Addictions in Pancreatic Cancer

Abstract 5712: Functional dissection of CDK7 in transcription using a highly selective CDK7 inhibitor Q901

CDK1 Promotes Nascent DNA Synthesis and Induces Resistance of Cancer Cells to DNA-damaging Therapeutic Agents.

CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins

Cytoprotective Role of Autophagy in CDIP1 Expression-Induced Apoptosis in MCF-7 Breast Cancer Cells

CDK7 in Breast Cancer: Mechanisms of Action and Therapeutic Potential.

The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer

Abstract A057: Therapeutic efficacy of selective CDK7 inhibition in pancreatic cancer mediated by induction of R-loop formation, DNA replication stress and genomic instability

Paraptosis—A Distinct Pathway to Cell Death